3 Pain and Anti-Malarial Brands, Branded Generics Marketer and Global Generics and Specialty Franchise Stocks With a Strong Future Roadmap: Ipca Laboratories, Emcure Pharmaceuticals and Lupin
- October 23, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Ipca Laboratories, Emcure Pharmaceuticals and Lupin: ROE of 14.2% to 23.8% and FY22 to FY26 revenue CAGR of 12.1% to 15.0%. Prices as of 22 Oct 2026.
Quick Answer
The three pain care and specialty generics stocks to watch are Ipca Laboratories, Emcure Pharmaceuticals and Lupin. Their return on equity ranges from 14.2% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Pain care and specialty generics stocks let investors follow pharmaceutical companies with strong brands and a growing global footprint. Ipca Laboratories, Emcure Pharmaceuticals and Lupin cover pain and anti-malarial brands, a branded generics marketer and a global generics and specialty franchise.
This list covers three pain care and specialty generics stocks with complete current figures: Ipca Laboratories, Emcure Pharmaceuticals and Lupin. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pain Care and Specialty Generics Stocks?
Pain care and specialty generics stocks are listed pharmaceutical companies that sell branded formulations at home and generics and specialty products overseas. Their earnings depend on brand growth, launches and plant capacity.
Pain Care and Specialty Generics Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Ipca Laboratories | 1,903.5 | 46,050 | 33.5 | 36.0 | 14.2 | 0.10 |
| Emcure Pharmaceuticals | 1,782.6 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Lupin | 1,922 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pain care and specialty generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pain care and specialty generics stocks can use the coming numbers to test whether growth is holding.
Why Do Pain Care and Specialty Generics Stocks Have a Strong Roadmap in India?
Pain care and specialty generics stocks have a strong roadmap in India because the domestic market keeps growing and Indian makers are moving up to more complex and specialty products.
- Brand depth. Established brands in pain and cardiac care earn steady repeat demand.
- Marketing arms. Dedicated field teams support new launches.
- Specialty products. Complex and specialty products earn better margins.
Why Ipca Laboratories Features Among These Pain Care and Specialty Generics Stocks
Among the pain care and specialty generics stocks on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.
In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%.
Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.
Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.
Why Emcure Pharmaceuticals Features Among These Pain Care and Specialty Generics Stocks
Among the cardiac and pain brand pharma shares on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Lupin Features Among These Pain Care and Specialty Generics Stocks
Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Ipca Laboratories vs Emcure Pharmaceuticals vs Lupin on Key Financials
The table below sets the three pain care and specialty generics stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Ipca Laboratories | 5,896 | 9,821 | 13.6% | 1,191 | 12.1% |
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin combines the largest FY26 revenue at Rs 29,039 crore with the fastest revenue growth, a 15.0% compound annual rate. A useful habit with pain care and specialty generics stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Ipca Laboratories | 2,342 | 2,813 | 20.2% |
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
| Lupin | 6,347 | 8,407 | 32.5% |
Key Risks to Check Before Investing in Pain Care and Specialty Generics Stocks
Every theme carries risks that deserve a check before any decision. For these pain care and specialty generics stocks, the main points are: Long-term cardiac and pain brand pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Price controls. Government limits on listed medicines can cap realisations.
- Regulatory checks. Plant inspections can delay launches.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pain care and specialty generics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pain Care and Specialty Generics Stocks
Pain care and specialty generics stocks reward investors who follow brand growth, launches and capacity together. Ipca Laboratories, Emcure Pharmaceuticals and Lupin each have a clear plan to expand. Based on the 22 October 2026 close, Ipca Laboratories trades at Rs 1,903.5, Emcure Pharmaceuticals at Rs 1,782.6 and Lupin at Rs 1,922. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pain care and specialty generics stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pain care and specialty generics stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pain care and specialty generics stocks?
Ans. Pain care and specialty generics stocks are listed pharmaceutical companies that sell branded formulations at home and generics and specialty products overseas. Their earnings depend on brand growth, launches and plant capacity. This list looks at three of them, Ipca Laboratories, Emcure Pharmaceuticals and Lupin, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which pain care and specialty generics stocks are covered in this list?
Ans. This list covers Ipca Laboratories, Emcure Pharmaceuticals and Lupin. Based on the 22 October 2026 close, Ipca Laboratories traded at Rs 1,903.5, Emcure Pharmaceuticals at Rs 1,782.6 and Lupin at Rs 1,922. Their return on equity ranges from 14.2% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 15.0%.
Why do pain care and specialty generics stocks have a strong future roadmap in India?
Ans. Pain care and specialty generics stocks have a strong roadmap in India because the domestic market keeps growing and Indian makers are moving up to more complex and specialty products. The main drivers are as follows. Brand depth. Established brands in pain and cardiac care earn steady repeat demand. Marketing arms. Dedicated field teams support new launches. Specialty products. Complex and specialty products earn better margins. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Ipca Laboratories performed financially?
Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What risks should investors check before buying pain care and specialty generics stocks?
Ans. Investors should check a few risks before buying pain care and specialty generics stocks. Price controls. Government limits on listed medicines can cap realisations. Regulatory checks. Plant inspections can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pain care and specialty generics stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.